MNPR, US61023L2079

Monopar Therapeutics stock holds at EUR 64.30 in late quote

Published on 10/30/2026 at 02:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Monopar Therapeutics stock was unchanged in the latest checked quote. The company is developing oncology radiopharmaceuticals and a Wilson Disease treatment.

Monopar quote and company profile

The latest checked quote was unchanged against the displayed previous value.
Monopar Therapeutics is developing radiopharmaceuticals for oncology and a treatment for Wilson Disease.
The company is a clinical-stage biotechnology business with several development programs.

MNPR, US61023L2079, Illustration mit AI erstellt.

Monopar Therapeutics stock was quoted at 64.30 euros in the latest Lang & Schwarz snapshot dated October 29, 2026, at 22:59:30 Berlin time. The displayed previous value was also 64.30 euros, so the snapshot showed no change. The quote is a market-data observation and does not establish a reason for the share price.

Clinical-stage pipeline remains central

According to the company's investor-relations website, Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease. Its stated pipeline includes MNPR-101-Zr for imaging, MNPR-101-Lu for therapy and the late-preclinical MNPR-101-Ac program.

The company also lists ALXN1840 as a late-stage treatment candidate for Wilson Disease. Its investor-relations page identifies the company as Monopar Therapeutics Inc. and lists MNPR as its ticker.

What the quote means for investors

The checked Lang & Schwarz value provides a dated euro-denominated reference point, while no verified Xetra closing basis was available for a same-session comparison. Investors should therefore distinguish this snapshot from a confirmed Xetra daily performance figure. The bid was 64.10 euros and the ask was 64.50 euros in the same data record.

For a direct view of the latest available quote, see the real-time quote of Monopar Therapeutics stock.

Monopar Therapeutics is part of the US equity market, where biotechnology valuations can remain sensitive to clinical progress, regulatory milestones and financing needs; this classification does not imply membership in a particular index. See the current market context around the S&P 500.

Further information is available in more news and analyses on Monopar Therapeutics stock.